4,500
Participants
Start Date
December 31, 2022
Primary Completion Date
February 29, 2028
Study Completion Date
May 31, 2028
Observation
Monitor every 6 months
Antiviral treatment
Receive first-line antiviral treatment, including entecavir, tenofovir disoproxil fumarate, tenofovir alafenamide, tenofovir amibufenamide or peginterferon
RECRUITING
Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing
RECRUITING
The Third Hospital of Changzhou, Changzhou
RECRUITING
The Fifth People's Hospital of Suzhou, Suzhou
RECRUITING
Huai'an No.4 People's Hospital, Huai'an
RECRUITING
Suqian People's Hospital, Suqian
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
OTHER